Press Releases

• March 10, 2022
  Cynapsus Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended 2015
• March 7, 2022
  Cynapsus Therapeutics Provides Company Update at Cowen & Co. 36th Annual Health Care Conference
• March 1, 2022
  Cynapsus to Present at Cowen & Co. 36th Annual Health Care Conference
• January 13, 2022
  Cynapsus Therapeutics to Present at Noble Financial Capital Markets Twelfth Annual Investor Conference
• January 7, 2022
  Cynapsus and Michael J. Fox Foundation Collaborate on Pilot Use of Wearable Device and Data Science Approaches in Phase 3 Parkinson’s Clinical Study
• January 4, 2022
  Cynapsus Therapeutics Completes Short-Form Amalgamation with Wholly-Owned Subsidiary
• December 10, 2021
  Cynapsus Announces Successful Completion of Bioavailability and Pharmacokinetic Study and Provides Update on European Clinical Plans
• December 8, 2021
  Cynapsus Therapeutics Announces Positive Data Presentations at World Congress on Parkinson’s Disease and Related Disorders Meeting
• November 19, 2021
  Cynapsus Therapeutics Expands Senior Leadership Team
• November 13, 2021
  Cynapsus Therapeutics to Present at Stifel 2015 Healthcare Conference
• November 12, 2021
  Cynapsus Reports Third Quarter 2015 Financial Results and Recent Developments
• September 3, 2021
  Cynapsus Therapeutics to Present at Two Upcoming Healthcare Conferences
• September 2, 2021
  Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Safety Study of APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease
• August 14, 2021
  Cynapsus Therapeutics Reports Second Quarter 2015 Financial Results and Recent Developments
• June 29, 2022
  Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Efficacy Study Evaluating Sublingual, Film Strip Delivery of Apomorphine to Turn Parkinson’s Disease Patients from the OFF to the ON State
• June 25, 2022
  Cynapsus Therapeutics’ APL-130277 Improved Parkinson’s Symptoms and Rapidly Turned Patients from OFF to ON in Data Presented at the International Congress of Parkinson's Disease and Movement Disorders
• June 23, 2022
  Cynapsus Therapeutics Inc. Closes US$72.5 Million Public Offering of Common Shares in the United States
• June 17, 2022
  Cynapsus Therapeutics Inc. Announces Pricing of US$63.0 Million Public Offering of Common Shares in the United States
• June 9, 2022
  Cynapsus Therapeutics Inc. Announces Launch of Proposed Public Offering of Common Shares in the United States
• June 4, 2022
  Cynapsus Therapeutics Announces Issuance of U.S. Patent Providing Broad Coverage for Sublingual Apomorphine
• May 15, 2022
  Cynapsus Therapeutics Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation
• May 8, 2022
  Cynapsus Therapeutics Reports First Quarter 2015 Financial Results and Recent Developments
• March 31, 2022
  Cynapsus Therapeutics Announces CAD$21 Million Private Placement
• March 17, 2022
  Cynapsus Therapeutics Reports 2014 Annual Results
• March 16, 2022
  Cynapsus to Host Analyst and Investor Breakfast in New York City on March 18
• March 12, 2022
  Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
• March 11, 2022
  Cynapsus Therapeutics Provides Clinical and Regulatory Update
• January 15, 2022
  Cynapsus to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference
• November 25, 2021
  Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange’s Senior Equity Market
• November 19, 2021
  Cynapsus Therapeutics Announces Positive Top-Line Results from CTH-105 Phase 2 Study of APL-130277
• November 18, 2021
  Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2021
• November 11, 2021
  Cynapsus Therapeutics Reports Third Quarter 2014 Financial Results and Recent Developments
• October 14, 2021
  Cynapsus Therapeutics’ Phase 2 Drug Candidate for Parkinson’s Chosen as One of the Top Ten Neurology Projects to Watch
• October 7, 2021
  Cynapsus Therapeutics Announces Hiring of New Chief Scientific Officer and EVP, CMC
• September 19, 2021
  Cynapsus Therapeutics Announces Change of Auditor
• August 13, 2021
  Cynapsus Therapeutics Reports Second Quarter 2014 Financial Results and Recent Developments
• July 17, 2022
  Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United States
• July 8, 2022
  Cynapsus Therapeutics Awarded Second Grant from The Michael J. Fox Foundation for Parkinson’s Research
• May 20, 2022
  Cynapsus Therapeutics Grants Stock Options
• May 14, 2022
  Cynapsus Announces No Buccal Mucosal Irritation in FDA Registration Study of APL-130277 for Parkinson’s Disease
• May 7, 2022
  Cynapsus Therapeutics Reports First Quarter 2014 Financial Results and Recent Developments
• April 24, 2022
  Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson’s Disease
• April 15, 2022
  Cynapsus Therapeutics Completes $25,000,000 Short Form Prospectus Offering
• April 8, 2022
  Cynapsus Therapeutics Files Final Short Form Prospectus
• March 28, 2022
  Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277
• March 28, 2022
  Cynapsus Therapeutics Files Preliminary Short Form Prospectus
• March 27, 2022
  Cynapsus Therapeutics Reports 2013 Financial Results and Highlights Key Developments
• February 27, 2022
  Cynapsus Therapeutics Announces DTC Approval
• February 13, 2022
  Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
• January 23, 2022
  Cynapsus Therapeutics Announces Exercise of Warrants
• January 22, 2022
  Cynapsus Announces Resignation of Chief Scientific Officer
• January 13, 2022
  Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
• November 21, 2021
  Cynapsus Therapeutics Reports Third Quarter 2013 Financial Results and Recent Developments
• August 22, 2021
  Cynapsus Therapeutics Reports Second Quarter 2013 Financial Results and Recent Developments
• July 18, 2022
  Cynapsus Therapeutics Begins Trading on the OTCQX Marketplace in the United States
• May 30, 2022
  Cynapsus Therapeutics to Present at the SeeThruEquity Second Annual Investor Conference on June 4, 2022 at 10:00 AM EDT
• May 28, 2022
  Cynapsus Therapeutics Grants Stock Options
• May 23, 2022
  Cynapsus Therapeutics Reports First Quarter 2013 Financial Results and Recent Developments
• May 15, 2022
  Cynapsus Publishes White Paper on Apomorphine for ‘Off’ Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277
• May 9, 2022
  Cynapsus Announces Completion of Short Form Prospectus Offering
• May 9, 2022
  Cynapsus Therapeutics Appoints Two New Directors
• May 1, 2022
  Cynapsus Therapeutics Grants Stock Options
• April 26, 2022
  Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key Developments
• March 21, 2022
  Cynapsus Raises Additional $1.3 Million As Part Of Short Form Prospectus Offering
• March 14, 2022
  Cynapsus Announces Continuation Of Short Form Prospectus Offering
• March 1, 2022
  Cynapsus Therapeutics Completes $6 Million Short Form Prospectus Offering
• February 22, 2022
  Cynapsus Therapeutics Files Final Short Form Prospectus
• December 11, 2021
  Cynapsus Therapeutics Receives Notice of Allowance from United States Patent and Trademark Office (USPTO)
• November 26, 2021
  Cynapsus Therapeutics Files Preliminary Short Form Prospectus
• November 23, 2021
  Cynapsus Announces Closing of Private Placement
• November 15, 2021
  Cynapsus Therapeutics Reports Third Quarter 2012 Financial Results and Recent Developments
• October 29, 2021
  Cynapsus Therapeutics’ APL 130277 For Parkinson’s Chosen As One Of The Top Ten Neurology Projects To Watch For 2012
• October 24, 2021
  Cynapsus Announces Closing of Private Placement
• October 3, 2021
  Cynapsus Therapeutics Signs Term Sheet for C$7 Million Offering
• August 29, 2021
  Cynapsus Therapeutics Reports Second Quarter 2012 Financial Results and Recent Developments
• August 8, 2021
  Cynapsus Therapeutics Awarded Grant from The Michael J. Fox Foundation
• July 18, 2022
  Cynapsus Announces Closing of Private Placement
• June 13, 2022
  Cynapsus Therapeutics Has Article Published in Journal of Commercial Biotechnology
• June 1, 2022
  BlueCross BlueShield policy gives boost to Cynapsus
• May 30, 2022
  Cynapsus Therapeutics Reports First Quarter 2012 Financial Results and Recent Developments
• May 17, 2022
  Cynapsus Therapeutics Retains US Investor Relations Firm
• May 3, 2022
  Cynapsus Therapeutics Nominates New Directors for Board
• April 23, 2022
  Cynapsus Therapeutics appoints Dr. Abraham Lieberman to Clinical Advisory Board
• April 16, 2022
  Cynapsus Provides Update and 2012 Outlook
• March 26, 2022
  Cynapsus Therapeutics Reports 2011 Financial Results and Highlights Key Developments
• March 9, 2022
  Cynapsus Therapeutics Announces $1 Million Financing
• February 13, 2022
  Cynapsus' President and CEO interview to air on Ichannel’s The Next Biggest Winner program
• January 10, 2022
  Cynapsus Announces Successful Human Volunteer Pilot Proof-of-Concept Results For APL-130277
• December 28, 2021
  Cynapsus Announces Debenture Financing
• December 22, 2021
  Cynapsus Therapeutics Announces Completed Acquisition of Adagio Pharmaceuticals
• December 15, 2021
  Cynapsus Announces Debenture Financing
• December 8, 2021
  Neurologist Survey Confirms Need for Improved Administration of Parkinson’s Disease Acute Rescue Therapy
• November 30, 2021
  Cynapsus Announces Results of Special Meeting of Shareholders
• November 23, 2021
  Cynapsus Announces Parkinson’s Drug Candidate Progress and Upcoming Milestones
• November 10, 2021
  Cynapsus Therapeutics Announces Third Quarter 2011 Financial Results and Recent Developments
• November 8, 2021
  Cynapsus Announces Debenture Financing
• September 29, 2021
  Cynapsus Announces Debenture Financing and Upcoming Milestones
• August 22, 2021
  Cynapsus Therapeutics Announces Second Quarter 2011 Financial Results and Recent Developments
• August 17, 2021
  Cynapsus Provides Update on Proposed Acquisition of Adagio Pharmaceuticals and Financing
• August 15, 2021
  IN VIVO: Will New Drugs For Motor Symptoms Of Parkinson's Disease Deliver?
• June 24, 2022
  Cynapsus Therapeutics Provides Research Update for Parkinson’s Drug Candidate
• June 21, 2022
  Cynapsus Provides Update on Brokered Private Placement
• June 17, 2022
  Cynapsus Therapeutics Announces First Quarter 2011 Financial Results and Recent Developments
• May 31, 2022
  Cynapsus Announces Results of Annual and Special Meeting of Shareholders
• May 31, 2022
  Cynapsus Therapeutics to Present at BioFinance 2011 Conference
• May 26, 2022
  Cynapsus Announces Debenture Financing
• May 25, 2022
  Cynapsus Therapeutics Signs Term Sheet for C$10 Million Private Placement Offering
• April 26, 2022
  Cynapsus Announces Proposed Acquisition of Adagio Pharmaceuticals and Private Placement
• April 12, 2022
  BioWorld Insight: Parkinson’s Update: Disease Pipeline Running the Gamut
• April 5, 2022
  The Burrill Report: An Interview With Anthony Giovinazzo, President and CEO, Cynapsus Therapeutics
• March 23, 2022
  BioPharm Insight: Cynapsus seeking CRO for studies of lead PD agent; plans to find global partner post completion of pivotal study - CEO
• March 22, 2022
  Cynapsus Announces Resignation of Chairman David Pattenden; Rochelle Stenzler Elected as New Chairperson
• March 7, 2022
  Cynapsus Therapeutics Announces Fourth Quarter and Full-Year 2010 Financial Results and Recent Developments
• February 18, 2022
  Cynapsus Therapeutics to Present at the BIOCOM Global Life Science Partnering Conference
• February 3, 2022
  Cynapsus Announces Closing of Private Placement
• January 28, 2022
  Cynapsus Announces Debenture Financing
• January 7, 2022
  Cynapsus President and CEO Provides Update with Open Letter
• January 4, 2022
  Cynapsus Announces Signing of Definitive License Agreement
• December 17, 2021
  Cynapsus Therapeutics Announces Transfer of Common Shares
• December 15, 2021
  Cynapsus Signs Engagement Letter With Summer Street Research Partners to Provide Financial and Advisory Services
• December 2, 2021
  Cynapsus Announces Positive Proof of Concept Results in Animals for Parkinson’s Drug Candidate
• November 29, 2021
  Cynapsus Announces Signing of Memorandum of Understanding
• November 24, 2021
  Cynapsus Announces Debenture Financing
• November 11, 2021
  Cynapsus Therapeutics Reports Results for the Nine Months Ended September 30, 2021
• November 8, 2021
  Cynapsus obtains survey results forecasting favourable acceptance of APL 130277 for Parkinson’s, by US HMOs and Insurers
• September 23, 2021
  Cynapsus Provides Research Update for Parkinson’s Drug Candidate
• August 13, 2021
  Cynapsus Therapeutics Reports Results for the Six Months Ended June 30, 2022
• August 5, 2021
  Cynapsus Announces Formation of Clinical Advisory Board For Parkinson’s Program
• August 4, 2021
  Cynapsus Announces Additional Debenture Financing
• July 29, 2022
  Cynapsus Announces Addition of Dr. Albert Agro to Parkinson’s Program Team
• July 27, 2022
  Cynapsus Announces Parkinson’s Disease Survey Results
• July 26, 2022
  Cynapsus Announces Signing of License Option Agreement of Parkinson’s Disease Technology
• July 19, 2022
  Cynapsus Announces Debenture Financing
• June 2, 2022
  Cynapsus Amends Terms and Conditions of Brokered Private Placement
• May 28, 2022
  Cynapsus Therapeutics Reports Results for the Three Months Ended March 31, 2022
• May 7, 2022
  Cynapsus Confirms Terms and Conditions of Brokered Private Placement
• April 15, 2022
  Cannasat Changes Name to Cynapsus Therapeutics
• April 7, 2022
  Cannasat Therapeutics Announces Private Placement
• April 6, 2022
  Cannasat Therapeutics to Present at BioFinance 2010 Conference
• March 9, 2022
  BioTuesday: Cannasat Batting Hot Streak in its CNS Turnaround
• March 5, 2022
  Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021
• March 4, 2022
  IntelGenx and Cannasat Announce Letter of Intent for Relivar License
• February 4, 2022
  Cannasat Announces Signing of Letter of Intent for In-licensing of Parkinson’s Disease Technology
• February 1, 2022
  Cannasat Update From Anthony Giovinazzo, President & CEO
• January 11, 2022
  Cannasat Therapeutics Strengthens its Board of Directors
• December 22, 2021
  Cannasat Therapeutics Announces Debt for Shares Settlement
• November 27, 2021
  Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2021
• November 16, 2021
  Cannasat Therapeutics Announces New Chief Executive Officer: Anthony J. Giovinazzo, M.B.A., C.Dir.
• August 31, 2021
  Cannasat Therapeutics Completes Prospectus Offering
• August 31, 2021
  Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2022
• August 6, 2021
  Cannasat Therapeutics Completes First Tranche of Prospectus Offering
• June 10, 2022
  Cannasat Therapeutics Prices Offering of Units
• May 29, 2022
  Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2022
• May 25, 2022
  Cannasat Therapeutics Announces Favourable Decision from United States Patent and Trademark Office
• May 19, 2022
  Cannasat Therapeutics Files Preliminary Short Form Prospectus
• May 15, 2022
  Cannasat Therapeutics names Nathan Bryson Chief Scientific Officer
• April 20, 2022
  Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021
• April 14, 2022
  Cannasat and IntelGenx Announce Positive Phase 1(b) Results: Improved buccal tablet outperforms oral dronabinol
• March 3, 2022
  Cannasat Therapeutics Announces Closing of Private Placement
• February 6, 2022
  Cannasat Therapeutics Inc. Announces $600,000 Financing
• January 28, 2022
  Cannasat to Commence Phase 1(b) Study of CAT 310, a Potential Treatment for Neuropathic Pain
• November 27, 2021
  Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2021
• August 29, 2021
  Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2022
• August 12, 2021
  Cannasat Therapeutics Announces Closing of Private Placement
• June 27, 2022
  Cannasat Therapeutics Grant of Options and Share Issuance
• June 23, 2022
  Cannasat Therapeutics Receives $1.12 Million from Divesture of Prairie Plant Systems Equity Position
• May 22, 2022
  Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2022
• April 10, 2022
  Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021
• March 18, 2022
  Cannasat Therapeutics Announces Closing of Private Placement
• February 27, 2022
  Cannasat Therapeutics Provides Update on Patent Application for Drug Development Programs
• January 14, 2022
  Cannasat Therapeutics appoints Dr. Julia Levy to Board of Directors
• January 14, 2022
  Cannasat Therapeutics appoints Dr. Julia Levy to Board of Directors
• December 4, 2021
  Cannasat and IntelGenx Complete Phase 1 Study for CAT 310
• November 28, 2021
  Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2021
• November 8, 2021
  Cannasat Therapeutics Retains Leading Investor Relations Firm
• October 30, 2021
  Cannasat Therapeutics Appoints George Nomikos as Senior Director, Scientific Affairs
• September 17, 2021
  Cannasat Therapeutics and IntelGenx Corp. Reach Key Milestone
• August 28, 2021
  Cannasat Therapeutics Reports Results for the Six Months Ended June 30, 2022
• August 23, 2021
  Cannasat Therapeutics to Commence Phase 1 Study of CAT 310, a Potential Treatment for Neuropathic Pain
• June 26, 2022
  Cannasat Therapeutics appoints Dr. David Pattenden as Chairman of the Board
• May 23, 2022
  Cannasat Therapeutics Reports Results for the Three Months Ended March 31, 2022
• April 25, 2022
  Cannasat Therapeutics Reports Results for the Year Ended December 31, 2021
• April 25, 2022
  Cannasat Therapeutics Inc. Announces Closing of Private Placement
• March 20, 2022
  Cannasat Therapeutics and IntelGenx enter into agreement to develop cannabinoid-based products for the treatment of mood disorders such as anxiety and depression.
• December 8, 2021
  Cannasat Therapeutics Inc. Grant of Options and Share Issuance
• December 6, 2021
  Cannasat Therapeutics Announces Successful pre-CTA Meeting with Health Canada Regarding CAT 310
• November 29, 2021
  Cannasat Therapeutics Reports Interim Results For The Nine Months Ended September 30, 2021
• November 14, 2021
  Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Cannabinoid-based Products Based on Proprietary Drug Delivery Technologies
• November 7, 2021
  Cannasat Therapeutics Inc. announces NRC-IRAP funding for CAT 210
• August 3, 2021
  Cannasat Therapeutics Inc. Announces Closing of Private Placement
• July 21, 2022
  Cannasat Therapeutics Inc. Announces New Terms for a Private Placement Financing
• June 7, 2022
  Cannasat Therapeutics Inc. Announces $5.0 Million Financing
• June 5, 2022
  Cannasat Therapeutics Inc. Announces New Director and Releases Q1 2006 Financial Statements
• April 5, 2022
  Cannasat Therapeutics now public on the TSX Venture Exchange
• March 22, 2022
  Cannasat Therapeutics Inc. and Lonsdale Public Ventures Inc. Announce Completion of Qualifying Transaction
• February 8, 2022
  Lonsdale Public Ventures Inc. Announcement Concerning Qualifying Transaction with Cannasat Therapeutics Inc.
• October 5, 2021
  Lonsdale Public Ventures Inc. Announces Letter Of Intent

The Burrill Report: An Interview With Anthony Giovinazzo, President and CEO, Cynapsus Therapeutics

April 5, 2022

Cynapsus Therapeutics is a small Canadian specialty pharma trying to reinvent itself. Under Anthony Giovinazzo, who took the helm at the end of 2009, the company has a new name and new focus. It’s hoping that its reformulation of an existing treatment for Parkinson’s disease can put it on a fast path to revenue with limited investment. We spoke to Giovinazzo about the company’s strategy, the advantages of its reformulated version of the long-standing drug apomorphine, and what lessons can be drawn from the company’s approach.

Link to Podast (Audio):

http://www.burrillreport.com/content/podcast/BRP-4-4-2011.mp3
 

Link to Page:

http://www.burrillreport.com/article-getting_back_on_track.html

Traded on